Here are relevant reports on : diabetes-devices-market
-
Diabetes Market (Devices and Drugs)
Sedentary lifestyle has led to the increase in diabetic patients and increasing awareness of side effects caused if left undiagnosed has increased the number of patients turning out for diagnosis and regular check. Additionally diabetes devices has also been a leading market in home healthcare segment as well, with introduction of handy glucose monitors. The market is evidencing continued innovation addressing issues pertaining to painless and user friendly diagnostic devices, drugs with less side effects, Insulin delivery systems etc. The market dynamics in this industry compels the competitors to be aware of the competitive moves to enhance market revenues and retain market share
- Published: February 2026
- Price: $ 4950
- TOC Available:
-
Diabetes Care Devices Market in Brazil, Russia, India, and China (BRIC) (2010 - 2014)
This market research report analyzes the diabetes care devices market in Brazil, Russia, India, and China (BRIC) over the period 2009-2014. The report categorizes the overall market for diabetes care devices into the submarkets for insulin pumps, self-monitoring blood glucose systems, and continuous glucose monitoring systems.
- Published: February 2026
- Price: $ 4950
- TOC Available:
-
North America Injectable Drug Delivery Market – by Formulations [Liposomes, Microspheres, & Nanoparticles], Devices [Disposables & Reusable, Fillable & Prefilled, Pen, Needle Free & Auto Injectors] & Therapeutics [Diabetes & Oncology] – Forecasts to 2017
The North American injectable drug delivery technologies market was valued at $9.3 billion in 2012; it is expected to reach $16.6 billion by 2017 at a CAGR of 12.3% from 2012 to 2017. Injectable drug delivery technologies are the combination of two major segments; devices and formulations. The North American injectable drug delivery formulations technologies market was the largest segment in this market. In addition, the market is segmented on the basis of its therapeutic applications. In therapeutic area, hormonal disorders command the major segment of injectable drug delivery technologies market due to high demand of injectable in treatment of diabetes. However, auto-immune diseases are the fastest growing segment of this market due to the advent of biologics (tumor necrosis factor (TNF) and Interleukin 1 (IL-1)) and improving patient compliance by the development of self injection devices.
- Published: April 2013
- Price: $ 4950
- TOC Available:
-
Medical Device Outsourced Manufacturing Market by Device Type (IVD (Equipment, Consumable), Diabetes, Respiratory, Cardiovascular, Personal Care, Endoscopy, Dental, Ophthalmology, Devices) Class of Device, Services, Procedure - Forecast to 2026
The global medical device outsourced manufacturing market growth is primed to transition from $29.3 billion in 2021 to $56.2 billion by 2026, showcasing a strong CAGR of 13.9%. The medical device outsourced manufacturing market is mainly driven by the overall growth of the medical devices market, mainly due to the rising disease prevalence, life expectancy, and geriatric population. Technological advancements have prompted end users to overhaul or update their manufacturing systems.
- Published: April 2021
- Price: $ 4950
- TOC Available:
-
Infusion Pump Market by Product (Accessories (Dedicated, Non-dedicated), Devices (Insulin, Syringe, Volumetric, Enteral, PCA Pump)), Technology (Traditional, Specialty), Mode (Stationary, Portable), Application (Cancer, Diabetes) - Global Forecast to 2030
The global infusion pump market, valued at US$18.5 billion in 2024, stood at US$19.9 billion in 2025 and is projected to advance at a resilient CAGR of 7.4% from 2025 to 2030, culminating in a forecasted valuation of US$ 28.3 billion by the end of the period. The infusion pump market is expanding rapidly, driven by significant technological advancements in smart, interconnected, and automated systems that optimize the precision and safety of infusion therapy.
- Published: June 2025
- Price: $ 4950
- TOC Available:
-
ASEAN Infusion Pump Market by Product (Accessories (Dedicated (Volumetric Pumps, Insulin Pumps, Enteral Pumps) & Non-dedicated), Devices (Traditional, Specialty)), Application (Oncology, Diabetes, Pain Management), End User - Global Forecast to 2030
The global ASEAN infusion pump market, valued at US$1.18 billion in 2024, stood at US$1.26 billion in 2025 and is projected to advance at a resilient CAGR of 7.1% from 2025 to 2030, culminating in a forecasted valuation of US$1.78 billion by the end of the period. The ASEAN infusion pump market is experiencing significant growth, driven by heightened healthcare awareness and enhanced access to sophisticated medical technologies throughout the region.
- Published: July 2025
- Price: $ 4950
- TOC Available:
-
Latin America Infusion Pump Market by Product (Accessories & Consumables, Devices (Volumetric, Insulin, Syringe, Ambulatory, PCA)), Application (Chemotherapy, Diabetes, Analgesia, Pediatrics, Hematology), End User (Hospitals) - Global Forecast to 2030
The global Latin America infusion pumps market, valued at US$707.6 million in 2024, stood at US$743.7 million in 2025 and is projected to advance at a resilient CAGR of 6.2% from 2025 to 2030, culminating in a forecasted valuation of US$1,004.9 million by the end of the period. The Latin America infusion pumps market is growing rapidly due to increasing healthcare awareness and improved access to advanced medical technologies across the region.
- Published: September 2025
- Price: $ 4950
- TOC Available:
-
Europe Digital Diabetes Management Market by Product (Device (CGM, Smart Glucometer, Insulin Patch Pump), Diabetes Apps, Service, Software & Platforms), Device Type (Handheld & Wearables), End User (Self/Home Healthcare) - Global Forecast to 2031
The Europe digital diabetes management market is projected to reach USD 12.53 billion by 2031 from USD 7.78 billion in 2026, at a CAGR of 10.0% during the forecast period. The Key Players include Medtronic (Ireland), B. Braun Melsungen AG (Germany), Dexcom, Inc. (US), Abbott Laboratories (US), F. Hoffmann-La Roche (Switzerland), Insulet Corporation (US), ARKRAY (Japan), ACON Laboratories, Inc. (US), Care Innovations, LLC (US), Health2Sync (Taiwan), Tandem Diabetes Care (US), Dottli (Finland), Ypsomed Holding AG (Switzerland), Emperra GmbH E-Health Technologies (Germany), Azumio (US), Ascensia Diabetes Care Holdings AG (Switzerland), LifeScan, Inc. (US), Tidepool (US), AgaMatrix (US), Glooko, Inc. (US), DarioHealth Corporation (Israel), Pendiq GmbH (Germany), One Drop (US), Decide Clinical Software GmbH (Austria), and BeatO (India)
- Published: February 2026
- Price: $ 4950
- TOC Available:
-
Digital Diabetes Management Market by Product (Device (CGM, Smart Glucometer, Insulin Patch Pump), Diabetes Apps, Service, Software & Platforms), Device Type (Handheld & Wearables), End User (Hospitals & Self/Home Healthcare) - Global Forecast to 2028
The global digital diabetes management market, valued at US$16.3 billion in 2022, stood at US$18.9 billion in 2023 and is projected to advance at a resilient CAGR of 13.6% from 2023 to 2028, culminating in a forecasted valuation of US$35.8 billion by the end of the period. The demand for better diabetes care solutions has grown of greater significance as diabetes prevalence has increased.
- Published: June 2023
- Price: $ 4950
- TOC Available:
-
US Digital Diabetes Management Market by Product (Device (CGM, Smart Glucometer, Insulin Patch Pump), Diabetes Apps, Service, Software & Platforms), Device Type (Handheld & Wearables), End User (Self/Home Healthcare) - Global Forecast to 2031
The US digital diabetes management market is projected to reach USD 22.67 billion by 2031 from USD 12.94 billion in 2026, at a CAGR of 11.9%. The Key Players include Medtronic (Ireland), B. Braun Melsungen AG (Germany), Dexcom, Inc. (US), Abbott Laboratories (US), F. Hoffmann-La Roche (Switzerland), Insulet Corporation (US), ARKRAY (Japan), ACON Laboratories, Inc. (US), Care Innovations, LLC (US), Health2Sync (Taiwan), Tandem Diabetes Care (US), Dottli (Finland), Ypsomed Holding AG (Switzerland), Emperra GmbH E-Health Technologies (Germany), Azumio (US), Ascensia Diabetes Care Holdings AG (Switzerland), LifeScan, Inc. (US), Tidepool (US), AgaMatrix (US), Glooko, Inc. (US), DarioHealth Corporation (Israel), Pendiq GmbH (Germany), One Drop (US), Decide Clinical Software GmbH (Austria), and BeatO (India)
- Published: February 2026
- Price: $ 4950
- TOC Available:
Records 1 to 10 of 50
